Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People taking part in the dose escalation part of the trial must have a confirmed cancer diagnosis (advanced or spread to other parts of the body) that has continued to grow despite standard treatment. Providing stored tumour tissue samples is required if they are available.
- People in the dose expansion part of the trial must have one of the following confirmed cancer types: melanoma that has stopped responding to a type of immunotherapy called anti-PD-(L)1 treatment (Module 1, Cohort 1); kidney cancer (RCC) that has stopped responding to anti-PD-(L)1 treatment (Module 1, Cohort 2); or melanoma being treated for the first time (Module 2, Cohort 1). A fresh tumour biopsy taken before treatment starts is required for all participants in the expansion part, with possible additional biopsies at other points during the trial.
Who may not be able to join:
- People who have previously received certain immune-stimulating therapies (called IL-2, IL-15, or IL-7) outside of a specific type of cell therapy treatment.
- People who have received anti-PD-1/PD-L1 immunotherapy, an approved systemic treatment, or certain other biological therapies within the past 4 weeks (confirm with trial site for full details).
- People who have had radiation therapy or major surgery within 14 days before the first study dose, or who are still recovering from side effects of these treatments.
- People who have received any prior anti-cancer immunotherapy within the past 4 weeks, or whose previous immunotherapy was stopped because of serious (grade 3 or 4) side effects.
- People who are still experiencing side effects related to their immune system from a previous treatment.
- People with a known allergy or sensitivity to any component of the study drug(s).
- People who need ongoing use of corticosteroid medicines (such as prednisone at more than 10 mg per day, or a similar anti-inflammatory medicine) within 1–2 weeks before the first study dose.
- People who have an active or recent history (within the past 5 years) of a significant autoimmune condition, or any condition that required treatment with medicines that suppress the immune system.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose-Limiting Toxicities (DLTs); Incidence of Treatment-Emergent Adverse Event (TEAEs); Incidence of Serious Adverse Events (SAEs); Incidence of TEAEs leading to treatment discontinuation; Incidence of TEAEs leading to death; Number of participants with Grade 3 laboratory abnormalities; Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria by investigator assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.